Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19

Int J Risk Saf Med. 2020;31(2):47-51. doi: 10.3233/JRS-201017.

Abstract

The ongoing COVID-19 pandemic has infected nearly 3,582,233 individuals with 248,558 deaths since it was first identified in human populations in December 2019 in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly neutralizing antibodies that bind to the specific antigens of SARS-CoV 2 might be a potential solution to address the immediate health threat of COVID-19 pandemic while vaccines are being developed. The PI approach in treating COVID-19 is discussed herein, including a summary of its historical applications to confront epidemics.

Keywords: COVID-19; convalescent plasma; coronaviruses; passive immunization.

MeSH terms

  • Antibodies, Viral / blood*
  • Antibodies, Viral / therapeutic use*
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • COVID-19 Serotherapy
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / therapy*
  • Humans
  • Immunization, Passive
  • Pandemics / prevention & control
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2

Substances

  • Antibodies, Viral